Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07173803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Progressive Supranuclear Palsy Clinical Trial Platform

Study acronym: PTP
StatusRecruiting
PhasePhase 2
SponsorAdam Boxer
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 12 → 18 locations
  2. Study sites: 12 to 13
  3. Trial sites expanded: 8 → 12 locations
  4. Eligibility criteria expanded, about 27 words
    • Site details revised at 1 of 8 sites
    • Collaborators: details revised at 2 of 6 entries
    • Study description expanded, about 2 words
  5. Trial sites expanded: 1 → 8 locationsv9
  6. Re-verified, no change to tracked fieldsv8
  7. Recruitment opened
    • Start date changed from estimate of Jun 30, 2026 to Jul 29, 2026
    • Site details revised
    v7
  8. Study sites: 0 to 1v6
  9. Primary and study completion dates: Jul 31, 2029 to Sep 28, 2030
    • Start date: Dec 1, 2025 to Jun 30, 2026
    v5
  10. Interventions: AADvac1 (Biological), Treatment B (Drug) to AADvac1 (Biological), LM11A-31 (Drug)
    • Study description shortened, about 1 word
    v4
  11. Interventions: AADvac1 (Biological), AZP006 (Ezeprogind®) (Drug) to AADvac1 (Biological), Treatment B (Drug)
    • Study description expanded, about 1 word
    v3
  12. Re-verified, no change to tracked fieldsv2
  13. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP.
Trial Details
NCT Number NCT07173803
Lead Sponsor Adam Boxer
Collaborators: National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, University of Southern California, Massachusetts General Hospital, University of California, San Diego, Alzheimer's Clinical Trials Consortium
Conditions
(from sponsor)		 Progressive Supranuclear Palsy(PSP)
Related terms Supranuclear Palsy, Progressive
Enrollment 440 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov